4 Health-Care Industry Predictions for the Next 20 Years

Page 1 of 2

It’s really amazing to think about how far we’ve come over even the past decade in the health-care arena. In that time we’ve seen heart disease and smoking rates drop dramatically, genome therapy has been brought directly to the patients’ bedside, and we have machines that can perform soft-tissue and orthopedic surgeries, as well as pinpoint and irradiate solid tumors. The rate of advancement recently is simply unparalleled.

But, of course, there’s still a lot more work to be done. There are far, far more uncured diseases out there than we’ve cured, and therefore plenty of trial, error, and opportunity still awaits. This is why today I want to look past the current advancements in health-care technologies and focus on the distant horizon — let’s say 20 years from now — and divvy out four predictions for the health-care industry as a whole.

Source: pop culture geek, Flickr.

Now understand that I have no crystal ball, nor do I have a DeLorean DMC-12 sitting in my garage that’ll let the sparks fly when I hit 88 mph and can take me ahead a few decades to see the future. These are merely personal projections that I expect to be held accountable for and for which I’ll back up my point of view — but ultimately, they are just predictions.

Prediction No. 1: Cancer will become the leading cause of death in the United States.
I’m sure that’s not the type of prediction you were probably hoping for, but hear me out. Over their lifetimes, men currently have about a 1-in-2 chance of developing some form of invasive cancer, while women have around a 1-in-3 chance. Although we’ve seen advancements in progression-free survival across many cancer types, and surgery and radiation techniques have become more precise, we are hardly any closer to finding a cure than we were 20 years ago. Take lung cancer and pancreatic cancer as perfect examples. In 1975-1977, the five-year survival rates of these cancer types was 12% and 2%, respectively. Fast-forwarding three decades to 2002-2008′s data, and these figures progressed to just 17% and 6%. We’re seeing progress, but a vast majority of it has come from better awareness of the risk factors for these cancer types instead of better medication. In essence, we’re nowhere near a cure.

The good news is that a lack of cure will offer an incredible opportunity for advancement in personalized patient care through genome analysis. Life Technologies and Illumina, Inc. (NASDAQ:ILMN) are two companies that have pioneered smaller genome sequencing technologies, which can process the human genome in 24 hours or less, and for little a fraction of the cost of genome analysis even 10 years ago. By better understanding cancerous genomes and how those cancers interact differently with each person, doctors may be able to use genome analysis to select the optimal therapy for a patient from the start rather than the current diagnosis structure, which involves a lot of trial and error. Illumina’s sequencing by synthesis technology is among the most accurate in the industry, and it’s certainly the name to keep your eye on here.

Prediction No. 2: U.S. obesity trends will reverse and could fall by as much as 25%.
I know it can be hard to imagine that U.S. obesity trend will actually taper, given the amount of fast-food restaurants in this country, but if history repeats itself, we should see a marked decline in obesity trends starting in about five to 10 years.

The basis for my prognostication lies with the reduced trends we’ve seen in smoking. Although smoking rates have been on the decline for decades, it wasn’t until the 1990s that U.S. health organizations really cracked down on the dangers of smoking, with their focus on reaching students and young adults.


Source: Center for Disease Control and Prevention.

There was a rapid drop-off in new smokers following these anti-smoking campaigns, but it took a few years for that message to completely resonate with the consumer and with students.

As it relates to obesity, we’re beginning to see some lifestyle changes sinking into the restaurant industry: Calories are being displayed on menus, fast-food restaurants are offering salads and other more nutritious selections, and the risk factors of being obese are being regularly highlighted by the Centers for Disease Control and Prevention, as well as other health organizations. Now, we just need to wait for these changes to really hit home with the consumer.

It could also represent a gigantic opportunity for chronic weight-management drugs such as VIVUS, Inc. (NASDAQ:VVUS)‘ Qsymia, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)‘ Belviq, and Orexigen Therapeutics‘ experimental drug Contrave. So far, Qsymia and Belviq have been an utter disappointment, but that could change with two factors: time and personalized medicine.

Time is a big factor for these companies, as Qsymia offered better weight percentage statistics, but Belviq has the more favorable safety profile. Over the next five years we should have a better bead on which treatment is superior. Furthermore, personalized medicine via genome analysis may spill over into the fight against obesity and could help researchers determine which anti-obesity medication is a best fit on a case-by-case basis.

Prediction No. 3: Hepatitis-C will be a 100% curable disease.
If there is a widespread disease that’s been beaten back with incredible efficacy over the past decade, it’s been liver disease hepatitis-C.

Before the emergence of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with Incivek and Merck with Victrelis, the overall response rate for peginterferon alfa and ribavirin, the then-current standard of treatment over 48 weeks was less than 50%. When Incivek gained approval in 2011, it was because it delivered a sustained virologic response (SVR) after 24 weeks of 79% (in other words, no traceable levels of the HCV virus was found), which was 20% to 45% higher than every placebo cohort it was tested against.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

Top 6 Cities For The Ultra Rich to Live in Comfort

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!